Empowered Patient Podcast

Thierry Abribat, Founder and CEO, Amolyt Pharma is developing a portfolio of products of peptides for rare endocrine and metabolic disorders. Their first project is a peptide hormone that is a parathyroid hormone being developed to treat hypoparathyroidism, a condition most often suffered by middle aged women and likely caused by thyroid surgery when the parathyroid glands are also removed. The alternate treatment being developed will address the current short term and long term burden these patients are facing with conventional therapy by better managing blood calcium, decreasing elimination of calcium through the kidneys and maintaining bone integrity.

@AmolytPharma

#TherapeuticPeptides #RareDiseases #EndocrineDisease #MetabolicDisease #Endocrinology #Hypoparathyroidism #Hypopara

AmolytPharma.com

Listen to the podcast here.

Thierry Abribat, Founder and CEO, Amolyt Pharma is developing a portfolio of products of peptides for rare endocrine and metabolic disorders. Their first project is a peptide hormone that is a parathyroid hormone being developed to treat hypoparathyroidism, a condition most often suffered by middle aged women and likely caused by thyroid surgery when the parathyroid glands are also removed. The alternate treatment being developed will address the current short term and long term burden these patients are facing with conventional therapy by better managing blood calcium, decreasing elimination of calcium through the kidneys and maintaining bone integrity.

@AmolytPharma

#TherapeuticPeptides #RareDiseases #EndocrineDisease #MetabolicDisease #Endocrinology #Hypoparathyroidism #Hypopara

AmolytPharma.com

Download the transcript here.

Dr. Edith Perez, Chief Medical Officer, Bolt Biotherapeutics discusses an innovative new platform for the treatment of patients with cancer. The Boltbody™ platform uses a combination of tumor targeting antibodies and localized stimulation of the immune system, or immune stimulating antibody conjugates, to fight cancer. Bolt's preclinical data show that in addition to killing the tumor, there is an immunological memory which helps to prevent tumors from growing back. Dr. Perez also discusses Bolt's first target HER2-expressing cancers, how the Boltbody™ platform is overcoming challenges treating this cancer and Bolt's current Phase 1 clinical trial.

@BoltBio #HER2 #Cancer #Boltbody

BoltBio.com

Listen to the podcast here.

Dr. Edith Perez, Chief Medical Officer, Bolt Biotherapeutics discusses an innovative new platform for the treatment of patients with cancer. The Boltbody™ platform uses a combination of tumor targeting antibodies and localized stimulation of the immune system, or immune stimulating antibody conjugates, to fight cancer. Bolt's preclinical data show that in addition to killing the tumor, there is an immunological memory which helps to prevent tumors from growing back. Dr. Perez also discusses Bolt's first target HER2-expressing cancers, how the Boltbody™ platform is overcoming challenges treating this cancer and Bolt's current Phase 1 clinical trial.

@BoltBio #HER2 #Cancer #Boltbody

BoltBio.com

Download the transcript here.

Mike Clayman, M.D., Chief Executive Officer and Co-Founder, Flexion Therapeutics brings us up to speed on the work at Flexion developing and commercializing new treatments for musculoskeletal disorders (MSDs) including osteoarthritis (OA) knee pain. Mike also talks about how the company has been adapting to the COVID-19 pandemic to get their drug Zilretta out to patients in need.

@FlexionInc #musculoskeletaldisorder #OAK #kneepain #osteoarthritisofknee #MSD #COVID19

FlexionTherapeutics.com

Listen to the podcast here

Mike Clayman, M.D., Chief Executive Officer and Co-Founder, Flexion Therapeutics brings us up to speed on the work at Flexion developing and commercializing new treatments for musculoskeletal disorders (MSDs) including osteoarthritis (OA) knee pain. Mike also talks about how the company has been adapting to the COVID-19 pandemic to get their drug Zilretta out to patients in need.

@FlexionInc #musculoskeletaldisorder #OAK #kneepain #osteoarthritisofknee #MSD #COVID19

FlexionTherapeutics.com

Download the transcript here

Lucia Faccio, Partner for the Sofinnova Telethon Fund at Sofinnova Partners talks about the recent creation of the Sofinnova Telethon Fund in Italy dedicated to early-stage investments in biotechnology companies that are addressing unmet medical needs of those suffering from rare and genetic diseases. Lucia is particularly enthusiastic about a recent investment in Genespire, company with a game changing technology providing a platform that is a lentiviral gene therapy for treatment of metabolic diseases and another gene editing platform with a focus on treating primary immunodeficiencies.

#SofinnovaPartners #Biotech #geneticdiseases #Funding

SofinnovaPartners.com

Listen to the podcast here

Lucia Faccio, Partner for the Sofinnova Telethon Fund at Sofinnova Partners talks about the recent creation of the Sofinnova Telethon Fund in Italy dedicated to early-stage investments in biotechnology companies that are addressing unmet medical needs of those suffering from rare and genetic diseases. Lucia is particularly enthusiastic about a recent investment in Genespire, company with a game changing technology providing a platform that is a lentiviral gene therapy for treatment of metabolic diseases and another gene editing platform with a focus on treating primary immunodeficiencies.

#SofinnovaPartners #Biotech #geneticdiseases #Funding

SofinnovaPartners.com

Download the transcript here

Myron Kowal, Owner and CEO, and Nick Garofoli, Director of Operations and Technology, RCare have developed wireless advanced nurse call systems that have been in use in a wide variety of hospital and assisted care settings. As a response to the COVID-19 outbreak, Myron and Nick describe the work they have done to deploy a rapid response solution to field hospitals allowing them to set up a 40-bed hospital in 15 minutes with the ability to track patients and beds using mobile technology with a user-friendly interface.

@ResponseCare #Nurses #COVID19 #RapidResponse

RCareInc.com

Download the transcript here

Myron Kowal, Owner and CEO, and Nick Garofoli, Director of Operations and Technology, RCare have developed wireless advanced nurse call systems that have been in use in a wide variety of hospital and assisted care settings. As a response to the COVID-19 outbreak, Myron and Nick describe the work they have done to deploy a rapid response solution to field hospitals allowing them to set up a 40-bed hospital in 15 minutes with the ability to track patients and beds using mobile technology with a user-friendly interface.

@ResponseCare #Nurses #COVID19 #RapidResponse

RCareInc.com

Download the transcript here